P122 Comparison of sleep estimation using Apple Watch accelerometry against polysomnography

por Roomkham, S, Lovell, D, Szollosi, I, Perrin, D
Publicado 2021

Chemical analysis of acid mucopolysaccharides of mixed salivary tumours.

por Lovell, D., Briggs, J. C., Schorah, C. J.
Publicado 1966

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

por Burmester, G R, Mease, P, Dijkmans, B A C, Gordon, K, Lovell, D, Panaccione, R, Perez, J, Pangan, A L
Publicado 2009

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovari...

por Coley, H M, Safuwan, N A M, Chivers, P, Papacharalbous, E, Giannopoulos, T, Butler-Manuel, S, Madhuri, K, Lovell, D P, Crook, T
Publicado 2012

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study

por De Benedetti, F, Ruperto, N, Brunner, HI, Grom, A, Wulffraat, N, Henrickson, M, Jerath, R, Kimura, Y, Kadva, AK, Wang, J, Martini, A, Lovell, D
Publicado 2013

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study

por De Benedetti, F, Ruperto, N, Brunner, H, Grom, A, Wulffraat, N, Henrickson, M, Jerath, R, Kimura, Y, Kadva, AK, Wang, J, Martini, A, Lovell, D
Publicado 2014

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data

por Ruperto, N, Brunner, HI, Kone-Paut, I, Magnusson, B, Ozen, S, Sztajnbok, F, Anton, J, Barash, J, Corona, F, Lheritier, K, Gaillez, C, Martini, A, Lovell, D
Publicado 2014

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)

por De Benedetti, F, Brunner, HI, Baildam, E, Burgos-Vargas, R, Horneff, G, Huppertz, HI, Minden, K, Myones, BL, Onel, K, Wang, J, Bharucha, K, Lovell, D, Martini, A, Ruperto, N
Publicado 2013

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients

por Wulffraat, NM, Ruperto, N, Brunner, HI, Oliveira, S, Uziel, Y, Nistala, K, Cimaz, R, Ferrandiz, MA, Flato, B, Gamir, M, Kone-Paut, I, Gaillez, C, Lheritier, K, Abrams, K, Martini, A, Lovell, D
Publicado 2014

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis

por Ruperto, N, Lovell, D, Goodman, S, Reiff, A, Nemcová, D, Quartier, P, Joos, R, Gerloni, V, Bohnsack, J, Wagner-Weiner, L, Huppertz, HI, Olson, N, Medich, J, McIlraith, M, Martini, A, Giannini, E
Publicado 2008

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study

por Mirjafari, H, Ruperto, N, Brunner, HI, Zuber, Z, Zulian, F, Maldonado-Velázquez, MR, Mantzourani, E, Murray, K, Roth, J, Rovensky, J, Vougiouka, O, Wang, J, Harari, O, Lovell, D, Martini, A, De Benedetti, F
Publicado 2013

PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the...

por Malattia, C, Ruperto, N, Palmisani, E, Pederzoli, S, Pistorio, A, Brunner, HI, Cuttica, R, Calvo, I, Garay, SM, Eleftheriou, D, Wouters, C, Wang, J, Devlin, C, Lovell, D, Martini, A, De Benedetti, F, Ravelli, A
Publicado 2013

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients

por Quartier, P, Ruperto, N, Wulffraat, N, Brunner, H, Brik, R, Mccann, L, Foster, H, Frosch, M, Gerloni, V, Harel, L, Len, C, Houghton, K, Joos, R, Abrams, K, Lheritier, K, Kessabi, S, Martini, A, Lovell, D
Publicado 2013

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis

por Quartier, P, Brunner, H, Constantin, T, Padeh, S, Calvo, I, Erguven, M, Goffin, L, Hofer, M, Kallinich, T, Oliveira, S, Uziel, Y, Viola, S, Nistala, K, Wouters, C, Lheritier, K, Hruska, J, Abrams, K, Martini, A, Ruperto, N, Lovell, D
Publicado 2013

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH

por De Benedetti, F, Ruperto, N, Zuber, Z, Cuttica, R, Xavier, R, Calvo, I, Rubio, N, Alekseeva, E, Chasnyk, V, Chavez, J, Horneff, G, Opoka-Winiarska, V, Quartier, P, Spindler, A, Keane, C, Bharucha, K, Wang, J, Lovell, D, Martini, A, Brunner, HI
Publicado 2013

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

por De Benedetti, F, Brunner, H, Ruperto, N, Schneider, R, Woo, P, Burgos-Vargas, R, Dolezalova, P, Joos, R, Wulffraat, N, Zuber, Z, Zulian, F, Allen, R, Brown, D, Chaitow, J, Pardeo, M, Espada, G, Flato, B, Gerloni, V, Horneff, G, Wright, S, Kenwright, A, Lovell, D, Martini, A
Publicado 2011

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever

por Horneff, G, Ruperto, N, Brunner, H, Quartier, P, Constantin, T, Alexeeva, E, Kone-Paut, I, Marzan, K, Wulffraat, N, Schneider, R, Padeh, S, Chasnyk, V, Wouters, C, Deschner, J Kummerle, Kallinich, T, Lauwerys, B, Haddad, E, Nasonov, E, Trachana, M, Vougiouka, O, Abrams, K, Leon, K, Lheritier, K, Martini, A, Lovell, D
Publicado 2015

Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment

por Johnson, G.E., Soeteman‐Hernández, L.G., Gollapudi, B.B., Bodger, O.G., Dearfield, K.L., Heflich, R.H., Hixon, J.G., Lovell, D.P., MacGregor, J.T., Pottenger, L.H., Thompson, C.M., Abraham, L., Thybaud, V., Tanir, J.Y., Zeiger, E., van Benthem, J., White, P.A.
Publicado 2014

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy

por Nirmala, N, Wulffraat, N, Brunner, H, Quartier, P, Brik, R, Mccann, L, Ozdogan, H, Rutkowska-Sak, L, Schneider, R, Gerloni, V, Harel, L, Terreri, M, Houghton, K, Joos, R, Kingsbury, D, Lopez-Benitez, J, Radominski, S, Brachat, A, Bek, S, Schumacher, M, Valentin, M, Gram, H, Abrams, K, Martini, A, Ruperto, N, Lovell, D
Publicado 2013

Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases

por Hinks, A, Bowes, J, Cobb, J, Ainsworth, H C, Marion, M C, Comeau, M E, Sudman, M, Han, B, Becker, M L, Bohnsack, J F, de Bakker, P I W, Haas, J P, Hazen, M, Lovell, D J, Nigrovic, P A, Nordal, E, Punnaro, M, Rosenberg, A M, Rygg, M, Smith, S L, Wise, C A, Videm, V, Wedderburn, L R, Yarwood, A, Yeung, R S M, Prahalad, S, Langefeld, C D, Raychaudhuri, S, Thompson, S D, Thomson, W
Publicado 2017